Apogee reports positive interim Phase 1 APG990 data with ~60-day half-life; 2024 net loss $182.1M

Apogee Therapeutics, Inc.

APG990 demonstrated ~60-day half-life, supporting every 3- and 6-month maintenance dosing; well tolerated up to 1,200 mg.
Combination APG279 (APG777+APG990) Phase 1b vs. DUPIXENT planned for 2025, readout expected H2 2026.
Full-year 2024 net loss $182.1M (vs. $84.0M in 2023); cash, equivalents and marketable securities $731.1M, runway into Q1 2028.
Phase 2 APEX trial for APG777 in atopic dermatitis over-enrolled Part A, Part B initiated; 16-week top-line data expected mid-2025.
R&D expenses $167.9M (up from $68.4M) driven by pipeline advancement and personnel costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.